AIM
CDTX

AXA Investment Managers’s Cidara Therapeutics CDTX Stock Holding History

AXA Investment Managers’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$5.86M Buy
+61,154
New +$3.9M 0.02% 532

Other funds holding CDTX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

AXA Investment Managers's CDTX Position: Q3 2025 in Review

AXA Investment Managers opened a new position in Cidara Therapeutics (CDTX) in Q3 2025: 61,154 shares worth $5.86M. The stake represents 0.02% of the portfolio and ranks #532 among its holdings.

173 funds tracked by Wall St. Rank hold CDTX as of Q3 2025.

  • AXA Investment Managers held 61,154 shares of Cidara Therapeutics worth $5.86M as of Q3 2025.
  • Cidara Therapeutics was a new AXA Investment Managers position in Q3 2025.
  • Cidara Therapeutics made up 0.02% of AXA Investment Managers's portfolio in Q3 2025, its #532 holding.
  • 173 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q3 2025.

Based on AXA Investment Managers's 13F filing for Q3 2025, filed 14 Nov 2025.